Evidence map›Paper›PMID 31842498›Full record

ArticleMolecules (Basel, Switzerland)2019

Coupling the Antimalarial Cell Penetrating Peptide TP10 to Classical Antimalarial Drugs Primaquine and Chloroquine Produces Strongly Hemolytic Conjugates.

Luísa Aguiar, Arnau Biosca, Elena Lantero, Jiri Gut, Nuno Vale, Philip J Rosenthal, Fátima Nogueira, David Andreu, Xavier Fernàndez-Busquets, Paula Gomes

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Enhanced Antimalarial Activity of Extracts ofChem & bio engineering · 2024
    Article
  4. Research advances in peptide‒drug conjugates.Acta pharmaceutica Sinica. B · 2023
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Luísa AguiarLAQV-REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, 4169-007 Porto, Portugal.
Arnau BioscaBarcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, 08036 Barcelona, Spain.
Elena LanteroBarcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, 08036 Barcelona, Spain.
Jiri GutSchool of Medicine, University of California at San Francisco, 1001 Potrero Avenue, San Francisco, San Francisco, CA 94110, USA.
Nuno ValeDepartamento de Farmacologia, Departamento de Ciências do Medicamento, Faculdade de Farmácia da Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.
Philip J RosenthalSchool of Medicine, University of California at San Francisco, 1001 Potrero Avenue, San Francisco, San Francisco, CA 94110, USA.
Fátima NogueiraGlobal Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, 1349-008 Lisbon, Portugal.
David AndreuDepartment of Experimental and Health Sciences, Pompeu Fabra University, Barcelona Biomedical Research Park, Dr. Aiguader 88, 08003 Barcelona, Spain.
Xavier Fernàndez-BusquetsBarcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, 08036 Barcelona, Spain.
Paula GomesLAQV-REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, 4169-007 Porto, Portugal.
Institute for Bioengineering of Catalonia · ESUniversidade do Porto · PTUniversidade Nova de Lisboa · PTUniversitat Pompeu Fabra · ES

Funding

CHROMATIN REMODELING AND MAMMARY GLAND DEVELOPMENTF32CA094579 · NCI · BAYLOR COLLEGE OF MEDICINE · PI KALLESEN, MICHELLE L · 2001 to 2001
$30k
Fundação para a Ciência e a Tecnologia IF/00092/2014/CP1255/CT0004Fundação para a Ciência e a Tecnologia PD/BD/106035/2015Fundação para a Ciência e a Tecnologia UID/QUI/50006/2019Ministerio de Ciencia, Innovación y Universidades RTI2018-094579-B-I00
6 · The paper itself

Abstract

Recently, we disclosed primaquine cell penetrating peptide conjugates that were more potent than parent primaquine against liver stage

Indexed as

AntimalarialsCell-Penetrating PeptidesChloroquinePrimaquineRecombinant Fusion ProteinsErythrocytesHumansPlasmodium falciparumAntimalarialsCell-Penetrating PeptidesChloroquinePrimaquineRecombinant Fusion Proteinstransportan-10antimalarialcell penetrating peptidechloroquineerythrocyte fluorescenceflow cytometryhemolysismicroscopyPlasmodiumprimaquinered blood cell

Identifiers

PMID31842498
PMCPMC6943437
OpenAlexW2996565937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.